Cue Health Partners with Actress Jamie-Lynn Sigler to Raise Awareness of At-Home, Same-Day Test-to-Treatment Platform for COVID-19 and Beyond
Jamie-Lynn Sigler and Cue Health Announce Product Donation to Multiple Sclerosis Association of America
SAN DIEGO, Oct. 6, 2022 /PRNewswire/ -- Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, has partnered with actress Jamie-Lynn Sigler, the actress best known for her roles on The Sopranos and ABC's Big Sky, to build awareness for its new Cue Care™ test-to-treatment service. With Cue Care, people who test positive for COVID-19 on any test, including antigen, can consult virtually and on-demand with a healthcare professional and easily access same-day prescription treatment delivered to their home all through the Cue Health App1.
"Living with multiple sclerosis puts me at higher risk for severe complications from COVID-19, something I faced head-on when I tested positive a couple months ago," commented Jamie-Lynn Sigler. "I was so uncertain at that moment about where to turn and what to do next to keep me and my family healthy. Cue can now solve that pain point for many people so they can easily get the medication and peace of mind they need when they need it the most."
"Jamie's experience shows exactly why Cue is committed to making treatment fast and accessible through Cue Care," added Clint Sever, co-founder and Chief Product Officer of Cue Health. "Today, Cue Care advances in the way people can test and get treatment for COVID-19, and over time it will enable people who test positive for a variety of infectious diseases to get treatment without leaving home."
Cue and Sigler are partnering to make a product donation of Cue Readers and Cue COVID-19 tests to the Multiple Sclerosis Association of America (MSAA), a leading resource for people like Sigler who are living with MS in the U.S. With this donation, the organization will be able to provide lab-quality COVID-19 testing to members of the community in their own homes who otherwise could be putting their health at risk by venturing to doctors' offices and pharmacies.
"The Multiple Sclerosis Association of America is grateful for the support of Cue Health and Jamie-Lynn Sigler, which allows us to provide Cue's COVID-19 tests and Readers to people who are simultaneously managing their MS and the potential impact of COVID-19," added Gina Ross Murdoch, MSAA's President ad CEO. "MSAA prides itself on improving the lives of those with MS, and partners like Cue and Jamie-Lynn help ensure that our clients can maintain their health and quality of life."
Cue's molecular COVID-19 test is the most accurate self-test2 available in the United States and provides results directly to a connected mobile device in 20 minutes. Cue is used in homes, hospitals and doctor's offices, and by world-class organizations across the country, including Google, Johns Hopkins Medicine, Mayo Clinic, the National Basketball Association, and Major League Baseball, among many others.
Cue Care, a service that is available in the Cue Health App, is expected to apply to a wide range of tests in the near future. These include, if approved, Cue flu and flu-COVID-19 molecular tests, along with tests for other respiratory infections like strep throat and respiratory syncytial virus (RSV), as well as sexually transmitted infections including chlamydia and gonorrhea. For more information about Cue Care and Cue's forthcoming products and services, please visit shop.cuehealth.com.
Jamie-Lynn Sigler headshot can be downloaded from HERE.
About Cue Health
Cue's COVID-19 tests have not been FDA cleared or approved; but have been authorized by FDA and under an Emergency Use Authorization (EUA). These products have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
1 Medications prescribed by independent healthcare professionals through Cue Care are subject to availability and patient eligibility. Cue Health Inc. is not affiliated with any pharmaceutical manufacturer.
2 Most accurate claim based on comparison of clinical study results submitted to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization for Cue and other molecular home tests.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cue-health-partners-with-actress-jamie-lynn-sigler-to-raise-awareness-of-at-home-same-day-test-to-treatment-platform-for-covid-19-and-beyond-301642151.html
SOURCE Cue Health Inc.
Quiet Quitting and Quiet Firing: What is Going on in the Workplace?
Session Details TBA